RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 FDA Opens Door to Obesity Pharmacotherapy
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 10
SP 14
OP 15
DO 10.1177/155989771310006
UL http://mdc.sagepub.com/content/13/10/14.abstract
AB Obesity drugs have eluded the United States Food and Drug Administration (FDA) approval process for 13 years, but with mechanisms of action identified and obesity recognized as a disease, that is changing. This article reviews the history of obesity pharmacology, present options in obesity pharmacotherapy, as well as the discovery of peptide-based mixed agonists based on glucagon.